rs778143946
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2
The NM_005431.2(XRCC2):c.509A>C(p.Glu170Ala) variant causes a missense change. The variant allele was found at a frequency of 0.0000347 in 1,614,092 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_005431.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
XRCC2 | NM_005431.2 | c.509A>C | p.Glu170Ala | missense_variant | Exon 3 of 3 | ENST00000359321.2 | NP_005422.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
XRCC2 | ENST00000359321.2 | c.509A>C | p.Glu170Ala | missense_variant | Exon 3 of 3 | 1 | NM_005431.2 | ENSP00000352271.1 | ||
XRCC2 | ENST00000495707.1 | n.531A>C | non_coding_transcript_exon_variant | Exon 3 of 3 | 1 | |||||
XRCC2 | ENST00000698506.1 | c.341A>C | p.Glu114Ala | missense_variant | Exon 2 of 2 | ENSP00000513758.1 |
Frequencies
GnomAD3 genomes AF: 0.0000591 AC: 9AN: 152204Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000278 AC: 7AN: 251380Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135852
GnomAD4 exome AF: 0.0000322 AC: 47AN: 1461888Hom.: 0 Cov.: 32 AF XY: 0.0000330 AC XY: 24AN XY: 727242
GnomAD4 genome AF: 0.0000591 AC: 9AN: 152204Hom.: 0 Cov.: 32 AF XY: 0.0000404 AC XY: 3AN XY: 74348
ClinVar
Submissions by phenotype
not provided Uncertain:3
This sequence change replaces glutamic acid, which is acidic and polar, with alanine, which is neutral and non-polar, at codon 170 of the XRCC2 protein (p.Glu170Ala). This variant is present in population databases (rs778143946, gnomAD 0.009%). This missense change has been observed in individual(s) with breast cancer (PMID: 23054243). ClinVar contains an entry for this variant (Variation ID: 409967). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt XRCC2 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change does not substantially affect XRCC2 function (PMID: 27233470). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
The XRCC2 c.509A>C (p.Glu170Ala) variant has been reported in the published literature in individuals with breast cancer (PMIDs: 23054243 (2012) and 28779002 (2017)). In a large scale breast cancer association study, this variant has been observed in 3 breast cancer cases and 2 reportedly healthy individuals (PMID: 33471991 (2021), see also LOVD (http://databases.lovd.nl/shared)). A functional study demonstrated that this variant does not alter the protein function (PMID: 27233470 (2016)). The frequency of this variant in the general population, 0.000087 (3/34590 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, we are unable to determine the clinical significance of this variant. -
Curator: Arleen D. Auerbach. Submitter to LOVD: Florentine Hilbers. -
Hereditary cancer-predisposing syndrome Uncertain:2
- -
The p.E170A variant (also known as c.509A>C), located in coding exon 3 of the XRCC2 gene, results from an A to C substitution at nucleotide position 509. The glutamic acid at codon 170 is replaced by alanine, an amino acid with dissimilar properties. In one study, this alteration was reported in 1/3548 non-BRCA1/2 familial breast cancer cases and 2/1435 healthy controls (Hilbers FS et al. J. Med. Genet., 2012 Oct;49:618-20). This alteration has also been reported in at least one subject in a study of 13087 breast cancer cases and 5488 control individuals in the UK (Decker B et al. J. Med. Genet., 2017 11;54:732-741). A cDNA complementation assay showed that the DNA repair efficiency of this alteration is similar to wild type (Hilbers FS et al. Hum. Mutat., 2016 09;37:914-25). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at